10 October 2024
IXICO plc
("IXICO" or the "Company")
Exercise of Options & Director/PDMR Purchase
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that it has issued, conditional on admission, 1,695,717 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options ("Options") under the Company's 2014 EMI Share Option Plan (the "2014 Plan"). 200,000 of these Options were exercised by Grant Nash, Chief Financial Officer and PDMR of the Company.
All tax and costs were paid separately by Mr Nash with no sale of Ordinary Shares required. Following this exercise, Mr Nash's holding has increased to 400,000 Ordinary Shares representing approximately 0.8% of the current Issued Share Capital of the Company.
In addition, Mark Warne, Chair of the Company has purchased 52,685 Ordinary Shares in the market. Following this purchase, Mr Warne's holding has increased to 72,335 representing approximately 0.14% of the current Issued Share Capital of the Company.
The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 14 October 2024.
Total Voting Rights
Following Admission, the Company will have 50,047,090 Ordinary Shares in issue. This figure of 50,047,090 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | ||
| Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
| ||
| |
| ||
| Cavendish Capital Markets Limited (Nominated adviser and sole broker) | +44 (0) 20 7220 0500 | ||
| Giles Balleny / Dan Hodkinson (Corporate Finance) | |
| |
| Nigel Birks (Life Sciences Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) | |
| |
|
|
|
| |
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Grant Nash | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Financial Officer and PDMR | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | IXICO plc
| ||||
| b) | LEI | 2138005M1F59O6HWSA97
| ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares in IXICO plc
ISIN: GB00BFXR4C20 | ||||
| b) | Nature of the transaction | Exercise of Options
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
N/A
| ||||
| e)
| Date of the transaction | 9 October 2024
| ||||
| f)
| Place of the transaction | Outside of a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Mark Warne | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chair and PDMR | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | IXICO plc
| ||||
| b) | LEI | 2138005M1F59O6HWSA97
| ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares in IXICO plc
ISIN: GB00BFXR4C20 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
52,685 Ordinary Shares 9.49 pence | ||||
| e)
| Date of the transaction | 9 October 2024 10 October
| ||||
| f)
| Place of the transaction | LSE/AIMX | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.